{"id":4896,"date":"2019-10-09T15:02:10","date_gmt":"2019-10-09T13:02:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/"},"modified":"2019-10-09T15:02:10","modified_gmt":"2019-10-09T13:02:10","slug":"riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/","title":{"rendered":"Riskonnect Partners with MG Select to Support Organizations Looking to Transition from MIDAS+"},"content":{"rendered":"
\n

\nPartnership combines deep patient safety and risk management capabilities with MIDAS+ expertise<\/i>\n<\/p>\n

ATLANTA–(BUSINESS WIRE)–Riskonnect<\/a>, the leading integrated risk management software solution provider serving 1200 hospitals and thousands of other healthcare organizations, has partnered with MG Select<\/a>, a professional services and strategic advisory firm, to assist companies transitioning away from legacy software platform MIDAS+.\n<\/p>\n

<\/a><\/p>\n

\n\u201cRiskonnect has been responding to a surge of interest from MIDAS+ healthcare clients looking for a more innovative and full-suite offering to manage a wide range of safety, quality and risk management initiatives,\u201d said Jim Wetekamp, Chief Executive Officer of Riskonnect. \u201cMG Select\u2019s expertise will help ensure client confidence as they adopt Riskonnect as their next generation patient safety and risk management solution.\u201d\n<\/p>\n

\nMG Select\u2019s core offerings include implementation, training and project management services that assist hospitals and other healthcare organizations in optimizing their existing solutions or more seamlessly transitioning to new ones. MG Select also has deep MIDAS+ domain experience.\n<\/p>\n

\n\u201cHealthcare quality and safety staff, having used MIDAS+ for their entire careers, are likely concerned about making a change,\u201d said Stephen Maddex, Sr. Vice President, Global Professional Services, Riskonnect. \u201cWe\u2019re pleased to add MG Select\u2019s MIDAS+ expertise to our implementation teams to help quell fears and ensure successful customer migrations from MIDAS+ to our integrated risk management platform.\n<\/p>\n

\n\u201cWe\u2019re impressed with Riskonnect\u2019s product and service capabilities and excited about the opportunity to help MIDAS+ clients move to an integrated platform that will help them better manage patient safety, claims and risk management practices, and quality performance improvement,\u201d says Karen LaRue, principal of MG Select.\n<\/p>\n

\nTo learn more about Riskonnect\u2019s integrated risk management platform, visit here<\/a>.\n<\/p>\n

\nAbout Riskonnect<\/b>\n<\/p>\n

\nRiskonnect is the leading integrated risk management software solution provider. Our technology empowers organizations with the ability to anticipate, manage, and respond in real-time to strategic and operational risks. More than 900 customers across six continents use our unique risk-correlation technology to gain previously unattainable insights that deliver desired outcomes. Riskonnect has more than 500 risk management experts in the Americas, Europe, and Asia. To learn more, visit www.riskonnect.com<\/a>.\n<\/p>\n

\nAbout Mitis Group Select (MG Select)<\/b>\n<\/p>\n

\nFounded in 2018, MG Select is a professional services company. MG Select helps healthcare organizations leverage and maximize their existing technology solutions by offering implementation, integration, data migration, system administration, education\/training, vendor evaluation and replacement services. MG Select also provides outsourcing services to software companies requiring project managers, program managers, and implementation specialists. To learn more, visit: https:\/\/www.mgselect.com<\/a>.\n<\/p>\n

\"\"<\/span><\/p>\n

Contacts<\/b> <\/p>\n

\nAbigail Holmes
\n
Corporate Ink for Riskonnect
\n
Riskonnect@corporateink.com<\/a>
+1-617-969-9192\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Partnership combines deep patient safety and risk management capabilities with MIDAS+ expertise ATLANTA–(BUSINESS WIRE)–Riskonnect, the leading integrated risk management software solution provider serving 1200 hospitals and thousands of other healthcare organizations, has partnered with MG Select, a professional services and strategic advisory firm, to assist companies transitioning away from legacy software platform MIDAS+. \u201cRiskonnect has … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["entry","post","publish","author-business","post-4896","format-standard","category-allgemein"],"yoast_head":"\nRiskonnect Partners with MG Select to Support Organizations Looking to Transition from MIDAS+ - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Riskonnect Partners with MG Select to Support Organizations Looking to Transition from MIDAS+ - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Partnership combines deep patient safety and risk management capabilities with MIDAS+ expertise ATLANTA–(BUSINESS WIRE)–Riskonnect, the leading integrated risk management software solution provider serving 1200 hospitals and thousands of other healthcare organizations, has partnered with MG Select, a professional services and strategic advisory firm, to assist companies transitioning away from legacy software platform MIDAS+. \u201cRiskonnect has ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-09T13:02:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20191009005081\/en\/723379\/21\/Riskonnect-Logo_Large.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Riskonnect Partners with MG Select to Support Organizations Looking to Transition from MIDAS+\",\"datePublished\":\"2019-10-09T13:02:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\\\/\"},\"wordCount\":441,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005081\\\/en\\\/723379\\\/21\\\/Riskonnect-Logo_Large.jpg\",\"articleSection\":[\"Allgemein\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\\\/\",\"name\":\"Riskonnect Partners with MG Select to Support Organizations Looking to Transition from MIDAS+ - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005081\\\/en\\\/723379\\\/21\\\/Riskonnect-Logo_Large.jpg\",\"datePublished\":\"2019-10-09T13:02:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005081\\\/en\\\/723379\\\/21\\\/Riskonnect-Logo_Large.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20191009005081\\\/en\\\/723379\\\/21\\\/Riskonnect-Logo_Large.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Riskonnect Partners with MG Select to Support Organizations Looking to Transition from MIDAS+\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Riskonnect Partners with MG Select to Support Organizations Looking to Transition from MIDAS+ - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/","og_locale":"en_US","og_type":"article","og_title":"Riskonnect Partners with MG Select to Support Organizations Looking to Transition from MIDAS+ - Pharma Trend","og_description":"Partnership combines deep patient safety and risk management capabilities with MIDAS+ expertise ATLANTA–(BUSINESS WIRE)–Riskonnect, the leading integrated risk management software solution provider serving 1200 hospitals and thousands of other healthcare organizations, has partnered with MG Select, a professional services and strategic advisory firm, to assist companies transitioning away from legacy software platform MIDAS+. \u201cRiskonnect has ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/","og_site_name":"Pharma Trend","article_published_time":"2019-10-09T13:02:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20191009005081\/en\/723379\/21\/Riskonnect-Logo_Large.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Riskonnect Partners with MG Select to Support Organizations Looking to Transition from MIDAS+","datePublished":"2019-10-09T13:02:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/"},"wordCount":441,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20191009005081\/en\/723379\/21\/Riskonnect-Logo_Large.jpg","articleSection":["Allgemein"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/","url":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/","name":"Riskonnect Partners with MG Select to Support Organizations Looking to Transition from MIDAS+ - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20191009005081\/en\/723379\/21\/Riskonnect-Logo_Large.jpg","datePublished":"2019-10-09T13:02:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20191009005081\/en\/723379\/21\/Riskonnect-Logo_Large.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20191009005081\/en\/723379\/21\/Riskonnect-Logo_Large.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/riskonnect-partners-with-mg-select-to-support-organizations-looking-to-transition-from-midas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Riskonnect Partners with MG Select to Support Organizations Looking to Transition from MIDAS+"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/4896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=4896"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/4896\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=4896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=4896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=4896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}